Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.
Identifieur interne : 001617 ( Main/Exploration ); précédent : 001616; suivant : 001618Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.
Auteurs : Keith C. Meyer [États-Unis] ; Catherine Decker ; Robert BaughmanSource :
- Clinics in chest medicine [ 1557-8216 ] ; 2010.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux (effets indésirables), Antimétabolites (effets indésirables), Benzamides, Chloroquine (effets indésirables), Cytotoxines (effets indésirables), Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Femelle, Grossesse, Hormones corticosurrénaliennes (effets indésirables), Humains, Hydroxychloroquine (effets indésirables), Immunosuppresseurs (effets indésirables), Immunosuppression thérapeutique (effets indésirables), Interactions médicamenteuses, Maladies auto-immunes (traitement médicamenteux), Mâle, Mésylate d'imatinib, Pipérazines (effets indésirables), Pyrimidines (effets indésirables).
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- effets indésirables : Anticorps monoclonaux, Antimétabolites, Chloroquine, Cytotoxines, Hormones corticosurrénaliennes, Hydroxychloroquine, Immunosuppresseurs, Immunosuppression thérapeutique, Pipérazines, Pyrimidines.
- traitement médicamenteux : Maladies auto-immunes.
- Benzamides, Femelle, Grossesse, Humains, Interactions médicamenteuses, Mâle, Mésylate d'imatinib.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (adverse effects), Antibodies, Monoclonal (adverse effects), Antimetabolites (adverse effects), Autoimmune Diseases (drug therapy), Benzamides, Chloroquine (adverse effects), Cytotoxins (adverse effects), Drug Interactions, Female, Humans, Hydroxychloroquine (adverse effects), Imatinib Mesylate, Immunosuppression (adverse effects), Immunosuppressive Agents (adverse effects), Male, Piperazines (adverse effects), Pregnancy, Pyrimidines (adverse effects), Tumor Necrosis Factor-alpha (antagonists & inhibitors).
- MESH :
- chemical , adverse effects : Adrenal Cortex Hormones, Antibodies, Monoclonal, Antimetabolites, Chloroquine, Cytotoxins, Hydroxychloroquine, Immunosuppressive Agents, Piperazines, Pyrimidines.
- adverse effects : Immunosuppression.
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- drug therapy : Autoimmune Diseases.
- chemical : Benzamides, Drug Interactions, Female, Humans, Imatinib Mesylate, Male, Pregnancy.
Abstract
Systemic autoimmune diseases may be progressive and lead to organ system dysfunction and premature death. Current treatment paradigms are usually predominantly based on the administration of immunosuppressive and/or immunomodulatory drug therapy. Such therapy can stabilize systemic manifestations of connective tissue disease (CTD) and may put the disease into remission, and many of these agents are commonly used to treat CTD-associated interstitial lung disease (ILD). Although these agents have largely revolutionized the treatment of the systemic autoimmune diseases, adverse reactions, which can be serious and life threatening, to the various immunosuppressive agents used in the treatment of CTD can occur. Treating physicians must be aware of mechanisms of action of various immunosuppressive agents and be able to recognize the potential adverse reactions that may occur with therapy as well as potentially harmful effects on fetal development. Appropriate monitoring may prevent or limit toxicity from these agents, and knowledge of drug-drug interactions is essential when these agents are prescribed.
DOI: 10.1016/j.ccm.2010.05.006
PubMed: 20692548
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000393
- to stream PubMed, to step Curation: 000393
- to stream PubMed, to step Checkpoint: 000380
- to stream Ncbi, to step Merge: 000140
- to stream Ncbi, to step Curation: 000140
- to stream Ncbi, to step Checkpoint: 000140
- to stream Main, to step Merge: 001620
- to stream Main, to step Curation: 001617
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.</title><author><name sortKey="Meyer, Keith C" sort="Meyer, Keith C" uniqKey="Meyer K" first="Keith C" last="Meyer">Keith C. Meyer</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA. kcm@medicine.wisc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Decker, Catherine" sort="Decker, Catherine" uniqKey="Decker C" first="Catherine" last="Decker">Catherine Decker</name></author><author><name sortKey="Baughman, Robert" sort="Baughman, Robert" uniqKey="Baughman R" first="Robert" last="Baughman">Robert Baughman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20692548</idno><idno type="pmid">20692548</idno><idno type="doi">10.1016/j.ccm.2010.05.006</idno><idno type="wicri:Area/PubMed/Corpus">000393</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000393</idno><idno type="wicri:Area/PubMed/Curation">000393</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000393</idno><idno type="wicri:Area/PubMed/Checkpoint">000380</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000380</idno><idno type="wicri:Area/Ncbi/Merge">000140</idno><idno type="wicri:Area/Ncbi/Curation">000140</idno><idno type="wicri:Area/Ncbi/Checkpoint">000140</idno><idno type="wicri:Area/Main/Merge">001620</idno><idno type="wicri:Area/Main/Curation">001617</idno><idno type="wicri:Area/Main/Exploration">001617</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.</title><author><name sortKey="Meyer, Keith C" sort="Meyer, Keith C" uniqKey="Meyer K" first="Keith C" last="Meyer">Keith C. Meyer</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA. kcm@medicine.wisc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Decker, Catherine" sort="Decker, Catherine" uniqKey="Decker C" first="Catherine" last="Decker">Catherine Decker</name></author><author><name sortKey="Baughman, Robert" sort="Baughman, Robert" uniqKey="Baughman R" first="Robert" last="Baughman">Robert Baughman</name></author></analytic><series><title level="j">Clinics in chest medicine</title><idno type="eISSN">1557-8216</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (adverse effects)</term><term>Antibodies, Monoclonal (adverse effects)</term><term>Antimetabolites (adverse effects)</term><term>Autoimmune Diseases (drug therapy)</term><term>Benzamides</term><term>Chloroquine (adverse effects)</term><term>Cytotoxins (adverse effects)</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Hydroxychloroquine (adverse effects)</term><term>Imatinib Mesylate</term><term>Immunosuppression (adverse effects)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Male</term><term>Piperazines (adverse effects)</term><term>Pregnancy</term><term>Pyrimidines (adverse effects)</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (effets indésirables)</term><term>Antimétabolites (effets indésirables)</term><term>Benzamides</term><term>Chloroquine (effets indésirables)</term><term>Cytotoxines (effets indésirables)</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Grossesse</term><term>Hormones corticosurrénaliennes (effets indésirables)</term><term>Humains</term><term>Hydroxychloroquine (effets indésirables)</term><term>Immunosuppresseurs (effets indésirables)</term><term>Immunosuppression thérapeutique (effets indésirables)</term><term>Interactions médicamenteuses</term><term>Maladies auto-immunes (traitement médicamenteux)</term><term>Mâle</term><term>Mésylate d'imatinib</term><term>Pipérazines (effets indésirables)</term><term>Pyrimidines (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Antibodies, Monoclonal</term><term>Antimetabolites</term><term>Chloroquine</term><term>Cytotoxins</term><term>Hydroxychloroquine</term><term>Immunosuppressive Agents</term><term>Piperazines</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunosuppression</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Autoimmune Diseases</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antimétabolites</term><term>Chloroquine</term><term>Cytotoxines</term><term>Hormones corticosurrénaliennes</term><term>Hydroxychloroquine</term><term>Immunosuppresseurs</term><term>Immunosuppression thérapeutique</term><term>Pipérazines</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies auto-immunes</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Benzamides</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Imatinib Mesylate</term><term>Male</term><term>Pregnancy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Benzamides</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Mâle</term><term>Mésylate d'imatinib</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Systemic autoimmune diseases may be progressive and lead to organ system dysfunction and premature death. Current treatment paradigms are usually predominantly based on the administration of immunosuppressive and/or immunomodulatory drug therapy. Such therapy can stabilize systemic manifestations of connective tissue disease (CTD) and may put the disease into remission, and many of these agents are commonly used to treat CTD-associated interstitial lung disease (ILD). Although these agents have largely revolutionized the treatment of the systemic autoimmune diseases, adverse reactions, which can be serious and life threatening, to the various immunosuppressive agents used in the treatment of CTD can occur. Treating physicians must be aware of mechanisms of action of various immunosuppressive agents and be able to recognize the potential adverse reactions that may occur with therapy as well as potentially harmful effects on fetal development. Appropriate monitoring may prevent or limit toxicity from these agents, and knowledge of drug-drug interactions is essential when these agents are prescribed.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Wisconsin</li></region></list><tree><noCountry><name sortKey="Baughman, Robert" sort="Baughman, Robert" uniqKey="Baughman R" first="Robert" last="Baughman">Robert Baughman</name><name sortKey="Decker, Catherine" sort="Decker, Catherine" uniqKey="Decker C" first="Catherine" last="Decker">Catherine Decker</name></noCountry><country name="États-Unis"><region name="Wisconsin"><name sortKey="Meyer, Keith C" sort="Meyer, Keith C" uniqKey="Meyer K" first="Keith C" last="Meyer">Keith C. Meyer</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001617 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001617 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20692548
|texte= Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20692548" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |